GILD Stock
Gilead Sciences, Inc. Common Stock
—
Price
Daily closes via Alpaca (IEX); today's point is the latest trade.
Key stats
Valuation
P/E (trailing)n/a
Forward P/E20.9
Price / sales6.7
Price / book14.3
EPS (12 mo)−$3.15
Dividend yield3.98%
Beta0.38
Financial health last 12 months
Revenue growth+6.5%
Gross margin80.0%
Net margin-12.5%
Return on equity-21.8%
Debt / equity2.22
Hover a figure for what it means.
Analyst ratings Nov 2026 · 36 analysts
Consensus: Buy
Strong buy 9Buy 21
Hold 6Sell 0
Strong sell 0
| Month | Buy | Hold | Sell | Consensus |
|---|---|---|---|---|
| Nov 2026 | 30 | 6 | 0 | Buy |
| Oct 2026 | 30 | 7 | 0 | Buy |
| Sep 2026 | 30 | 7 | 0 | Buy |
| Aug 2026 | 30 | 7 | 0 | Buy |
Latest news
Is It Too Early To Buy Insmed Stock?
Yahoo · 1d ago
Should You Buy Exelixis Stock For Its Cash?
Yahoo · 2d ago
Where Could Gilead's Next Growth Come From?
Yahoo · 2d ago
How Many Shares of Bristol Myers Squibb, Merck or Gilead Sciences Pay $1,000 a Month in Dividends?
Yahoo · 3d ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Yahoo · 3d ago
Headlines from the last 10 days via Finnhub; links open the publisher's article.
Next earnings
No report scheduled in the next 4 months.
Past earnings moves
No tracked reports yet. TradeSphere saves the expected and actual move for every report from Nov 3, 2026 on, for stocks on the Earnings page.